![]() In reaching an accurate diagnosis sooner, the significant psychosocial morbidity and excess mortality of BP may be lowered, along with the higher costs of care incurred by a delayed diagnosis. 1 While diagnostic errors may never completely be eliminated, it is important to lessen their likelihood by better understanding the diagnostic criteria for MDD and both bipolar I (BP I) and bipolar II (BP II) disorders as well as the many psychiatric disorders and medical conditions that may have overlapping symptoms. Both overdiagnosis and underdiagnosis of BP are all too common, and it may take a decade or longer to reach a correct diagnosis. ![]() Given the similarity in clinical presentation between major depressive disorder (MDD) and the depressive episodes of bipolar disorder (BP), it is inevitable that diagnostic errors will occur. ![]() © Copyright 2019 Phy sicians Postgraduate Press, Inc. To cite: Differential diagnosis of major depressive disorder versus bipolar disorder: current status and best clinical practices. This article is distributed by Otsuka Pharmaceutical Development & Commercialization, Inc., and Lundbeck, LLC, Deerfield, IL, USA, for educational purposes only. The opinions expressed herein are those of the faculty and do not necessarily reflect the views of Healthcare Global Village, Inc., the publisher, or the commercial supporters. The faculty acknowledges Nancy Groves & Associates for editorial assistance in developing the manuscript. Financial support for preparation and dissemination of this Academic Highlights was provided by Otsuka Pharmaceutical Development & Commercialization, Inc., and Lundbeck, LLC, Deerfield, IL, USA. This evidence-based peer-reviewed Academic Highlights was prepared by Healthcare Global Village, Inc. ![]() Dr First has received consultant fees as a member of the faculty of the Lundbeck International Neuroscience Foundation. Dr Goldberg has received consultant fees from Lundbeck, Neurocrine, Otsuka, Sunovion, and WebMD and has served on speaker/advisory boards for Allergan, Neurocrine, Otsuka, Sunovion, and Takeda-Lundbeck. Dr Zimmerman has received consultant fees from Otsuka and Praxis Precision Medicines and has served on a speaker/advisory board for Alkermes. First, MD, Department of Psychiatry, Columbia University, New York, New York.įinancial disclosures: Dr McIntyre has received research or grants from private industries or nonprofit funds from Stanley Medical Research Institute and CIHR/GACD/Chinese National Natural Research Foundation and has received consultant/speaker fees from Lundbeck, Janssen, Shire, Purdue, Pfizer, Otsuka, Allergan, Takeda, Neurocrine, Sunovion, and Minerva. Goldberg, MD, Icahn School of Medicine at Mount Sinai, New York, New York and Michael B. The faculty were Mark Zimmerman, MD, Rhode Island Hospital, Providence, Rhode Island Joseph F. McIntyre, MD, FRCPC, Department of Psychiatry & Pharmacology, University of Toronto Mood Disorders Psychopharmacology Unit, University Health Network, Toronto, Ontario, Canada. The live roundtable discussion was chaired by Roger S. The purpose of this article is to provide psychiatrists and other health care professionals who treat patients with major depressive disorder and bipolar disorder a set of best practices, tools, and other methods to improve their ability to make a more accurate diagnosis between major depressive disorder and bipolar disorder and to reach this diagnosis sooner, given a particular set of patient-related circumstances and comorbidities. This evidence-based Academic Highlights section of The Journal of Clinical Psychiatry was derived from survey and focus group data, faculty presentations, and discussions between experts captured during the roundtable meeting “Differential Diagnosis of Major Depressive Disorder Versus Bipolar Disorder: Current Status and Best Clinical Practices,” which was held October 26, 2018, in Orlando, Florida.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |